Keybank National Association OH decreased its stake in shares of Celgene Co. (NASDAQ:CELG) by 29.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 577,514 shares of the biopharmaceutical company’s stock after selling 245,105 shares during the quarter. Keybank National Association OH owned about 0.07% of Celgene worth $60,269,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the business. Retirement Systems of Alabama increased its stake in Celgene by 18.1% during the 4th quarter. Retirement Systems of Alabama now owns 643,943 shares of the biopharmaceutical company’s stock valued at $67,202,000 after purchasing an additional 98,683 shares in the last quarter. Weatherstone Capital Management increased its stake in Celgene by 16.3% during the 4th quarter. Weatherstone Capital Management now owns 3,899 shares of the biopharmaceutical company’s stock valued at $407,000 after purchasing an additional 547 shares in the last quarter. Willingdon Wealth Management increased its stake in Celgene by 77.4% during the 4th quarter. Willingdon Wealth Management now owns 33,827 shares of the biopharmaceutical company’s stock valued at $3,530,000 after purchasing an additional 14,757 shares in the last quarter. American Research & Management Co. increased its stake in Celgene by 6.5% during the 4th quarter. American Research & Management Co. now owns 21,990 shares of the biopharmaceutical company’s stock valued at $2,295,000 after purchasing an additional 1,335 shares in the last quarter. Finally, Trust Co. of Toledo NA OH increased its stake in Celgene by 10.4% during the 4th quarter. Trust Co. of Toledo NA OH now owns 6,625 shares of the biopharmaceutical company’s stock valued at $692,000 after purchasing an additional 622 shares in the last quarter. Institutional investors and hedge funds own 78.60% of the company’s stock.
Celgene Co. (NASDAQ:CELG) opened at $86.91 on Friday. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29. The stock has a market cap of $66,424.63, a price-to-earnings ratio of 12.87, a price-to-earnings-growth ratio of 0.62 and a beta of 1.58. Celgene Co. has a twelve month low of $86.55 and a twelve month high of $147.17.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The business had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The company’s revenue was up 16.9% compared to the same quarter last year. During the same period last year, the firm posted $1.61 earnings per share. equities research analysts predict that Celgene Co. will post 7.66 EPS for the current year.
Celgene declared that its board has initiated a stock buyback plan on Wednesday, February 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.
CELG has been the topic of a number of research reports. Mizuho reiterated a “buy” rating and issued a $128.00 price objective on shares of Celgene in a research note on Sunday, February 4th. Credit Suisse Group set a $125.00 price objective on shares of Celgene and gave the stock a “buy” rating in a research note on Monday, January 8th. Cann reiterated a “buy” rating and issued a $163.00 price objective on shares of Celgene in a research note on Thursday, February 15th. Vetr lowered shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price objective on the stock. in a research note on Monday, December 18th. Finally, Oppenheimer set a $166.00 price objective on shares of Celgene and gave the stock a “buy” rating in a research note on Thursday, December 14th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and an average target price of $127.78.
In related news, insider Mark J. Alles acquired 3,260 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were acquired at an average cost of $91.90 per share, with a total value of $299,594.00. Following the completion of the acquisition, the insider now directly owns 178,904 shares in the company, valued at approximately $16,441,277.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $95.99, for a total transaction of $887,907.50. Following the transaction, the director now directly owns 94,801 shares in the company, valued at $9,099,947.99. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,120 shares of company stock worth $3,879,509. Insiders own 0.95% of the company’s stock.
WARNING: This story was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://ledgergazette.com/2018/03/23/celgene-co-celg-holdings-cut-by-keybank-national-association-oh.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.